FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri/File Photo
July 28, 2021
(Reuters) – Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany’s BioNTech to $33.5 billion from $26 billion, the second increase this year in the face of a global scramble for the shots.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
Source: One America News Network
